Using GLP1 receptor agonists to treat cardiac patients with diabetes
At our 2018 symposium, "Management of Type 2 Diabetes in Patients with CVD: Focus on Heart Failure," Sunnybrook's Dr. Julie Lovshin explores GLP1 receptor agonist therapy in the setting of type 2 diabetes.
▶︎
Exploring the Science and Practice of GLP-1 Receptor Agonists
▶︎
Professor Milton Packer - 'Heart failure – are there limits to anti-diabetic therapy with SGLT2'
▶︎
Management of Comorbidities in Patients with Diabetes
▶︎
Using SGLT2-inhibitors to treat cardiac patients with diabetes
▶︎
The Role of GLP1 Agonists in Cardiovascular Care, Beyond Weight Loss – A Q&A Session
▶︎
How do GLP-1 Agonists Work? (EASY Pharmacology)
▶︎
The Story of GLP-1: Episode 1 - "A diabetes doctor’s dream"
▶︎
Insulin Treatment in Patients with Type 2 Diabetes
▶︎
SGLT2 Inhibitors vs GLP-1 Agonists: A Cardiologist and an Endocrinologist Weigh In
▶︎
Targeting GIP and GLP-1 to Individualize Treatment in Patients With T2DM and Obesity
▶︎
Diabetes Drugs (Oral Antihyperglycemics & Insulins)
▶︎
How Do Ozempic, Mounjaro & Other GPL-1 Agonists Work? | Dr. Zachary Knight & Dr. Andrew Huberman
▶︎
LADA (Latent Autoimmune Diabetes in Adults)
▶︎
Highly Successful Weight Loss Drug Semaglutide Explained
▶︎
SGLT2 Inhibition for the Prevention and Treatment of Kidney Disease in Patients With Type 2 Diabetes
▶︎
Drug Allergy Update: Diagnosis, Management, and Implications - Grand Rounds HHS
▶︎
Choosing SGLT2 Inhibitors vs GLP-1 Receptor Agonists
▶︎
The Increasing Importance of GLP-1–Based Therapies for Personalized Obesity Management
▶︎
Management of Diabetes in 2023: Updates and Future Directions
▶︎